Cwm, LLC Bio N Tech Se Transaction History

Cwm, LLC

$25.1 Billion
Q1 2025

A detailed history of Cwm, LLC transactions in Bio N Tech Se stock. As of the latest transaction made, Cwm, LLC holds 332 shares of BNTX stock, worth $36,569. This represents 0.0% of its overall portfolio holdings.

Number of Shares

332

Previous 306 8.5%

Holding current value

$36,569

Previous $35,000 14.29%

% of portfolio

0.0%

Previous 0.0%

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 01, 2025	BUY	$91.06 - $126.88 $2,367 - $3,298	26 Added 8.5%	332 $30,000
Q4 2024 Feb 04, 2025	SELL	$99.72 - $122.68 $3,091 - $3,803	-31 Reduced 9.2%	306 $35,000
Q3 2024 Oct 08, 2024	SELL	$78.36 - $124.66 $75,617 - $120,296	-965 Reduced 74.12%	337 $40,000
Q2 2024 Jul 09, 2024	SELL	$80.36 - $102.87 $8,036 - $10,287	-100 Reduced 7.13%	1,302 $105,000
Q1 2024 Apr 05, 2024	BUY	$88.96 - $112.35 $102,481 - $129,427	1,152 Added 460.8%	1,402 $129,000
Q4 2023 Feb 01, 2024	BUY	$90.91 - $112.75 $19,727 - $24,466	217 Added 657.58%	250 $26,000
Q3 2023 Oct 11, 2023	SELL	$98.5 - $125.08 $2,462 - $3,127	-25 Reduced 43.1%	33 $4,000
Q2 2023 Aug 03, 2023	SELL	$102.58 - $129.66 $2,564 - $3,241	-25 Reduced 30.12%	58 $6,000
Q1 2023 Apr 28, 2023	BUY	$122.57 - $153.67 $9,192 - $11,525	75 Added 937.5%	83 $10,000
Q4 2022 Feb 01, 2023	SELL	$118.43 - $186.05 $5,921 - $9,302	-50 Reduced 86.21%	8 $1,000
Q3 2022 Oct 27, 2022	SELL	$127.65 - $183.11 $1,914 - $2,746	-15 Reduced 20.55%	58 $8,000
Q1 2022 Apr 21, 2022	BUY	$126.25 - $231.85 $126 - $231	1 Added 1.39%	73 $12,000
Q4 2021 Jan 31, 2022	BUY	$216.64 - $362.52 $15,598 - $26,101	72 New	72 $18,000

Others Institutions Holding BNTX

# of Institutions

340

Shares Held

40M

Call Options Held

1.43M

Put Options Held

1.54M

View Full List

About BioNTech SE

Ticker BNTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 242,684,992
Market Cap $26.7B
Description
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II...

More about BNTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Cwm, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cwm, LLC with notifications on news.

Account